Status:
ACTIVE_NOT_RECRUITING
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Lead Sponsor:
AbbVie
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax works to treat AML in adult particip...
Eligibility Criteria
Inclusion
- Diagnosis of Acute Myeloid Leukemia (AML).
- Ineligible for intensive chemotherapy, determined by the physician's assessment of age, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), comorbidities, regional guidelines, and institutional practice.
- Participant for whom the physician has decided to initiate venetoclax treatment in accordance with the local label. The decision to treat with venetoclax is made by the physician prior to any decision to approach the participant to participate in this study.
Exclusion
- \- Participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.
Key Trial Info
Start Date :
September 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2027
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT05424562
Start Date
September 7 2022
End Date
March 1 2027
Last Update
November 28 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Baker Cancer Centre /ID# 248113
Calgary, Alberta, Canada, T2N 4N2
2
University of Alberta Hospital /ID# 251531
Edmonton, Alberta, Canada, T6G 2B7
3
BC Cancer - Surrey /ID# 257515
Surrey, British Columbia, Canada, V3V 1Z2
4
Vancouver General Hospital /ID# 245438
Vancouver, British Columbia, Canada, V5Z 1M9